We are live on ! Find out more
NBIX icon

Neurocrine Biosciences
NBIX

126 hedge funds and large institutions have $759M invested in Neurocrine Biosciences in 2013 Q2 according to their latest regulatory filings, with 126 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

45% more call options, than puts

Call options by funds: $14.3M | Put options by funds: $9.91M

Holders
126
Holders Change
+126
Holders Change %
–
% of All Funds
4.11%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.07%
New
126
Increased
–
Reduced
–
Closed
–
Calls
$14.3M
Puts
$9.91M
Net Calls
+$4.43M
Net Calls Change
+$4.43M

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$127M +$116M +9,459,212 New
T. Rowe Price Associates
2
T. Rowe Price Associates
Maryland
$105M +$96.7M +7,868,859 New
PA
3
Perceptive Advisors
New York
$68M +$62.4M +5,081,717 New
BFA
4
BlackRock Fund Advisors
California
$28.5M +$26.1M +2,126,438 New
State Street
5
State Street
Massachusetts
$27.1M +$24.9M +2,025,918 New
VM
6
VHCP Management
New York
$26.3M +$24.1M +1,964,673 New
VAM
7
Visium Asset Management
New York
$26.1M +$23.9M +1,948,220 New
BIT
8
BlackRock Institutional Trust
California
$25.3M +$23.3M +1,893,820 New
Vanguard Group
9
Vanguard Group
Pennsylvania
$24.2M +$22.2M +1,808,384 New
Jennison Associates
10
Jennison Associates
New York
$22.1M +$20.3M +1,652,646 New
TI
11
Turner Investments
Pennsylvania
$20.8M +$19.1M +1,556,686 New
Franklin Resources
12
Franklin Resources
California
$19.4M +$17.8M +1,448,400 New
Deutsche Bank
13
Deutsche Bank
Germany
$15.8M +$14.5M +1,177,769 New
PC
14
PointState Capital
New York
$15.1M +$13.8M +1,125,000 New
Northern Trust
15
Northern Trust
Illinois
$13.6M +$12.5M +1,013,915 New
O
16
OrbiMed
New York
$10.3M +$9.43M +768,000 New
TCM
17
Tekla Capital Management
Massachusetts
$9.47M +$8.7M +707,990 New
PC
18
Polar Capital
United Kingdom
$9.37M +$8.6M +700,199 New
SCA
19
SAC Capital Advisors
Connecticut
$9.37M +$8.6M +700,000 New
RG
20
Redmile Group
California
$7.77M +$7.13M +580,500 New
Bank of New York Mellon
21
Bank of New York Mellon
New York
$6.82M +$6.27M +509,993 New
DCM
22
Driehaus Capital Management
Illinois
$6.71M +$6.16M +501,319 New
UBS AM
23
UBS AM
Illinois
$6.31M +$5.79M +471,398 New
CCM
24
Cupps Capital Management
Illinois
$5.78M +$5.31M +431,896 New
Allianz Asset Management
25
Allianz Asset Management
Germany
$5.77M +$5.3M +431,500 New
1
2 3 4 5

NBIX Hedge Fund Activity: Q2 2013 in Review

126 of the 3,064 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q2 2013, worth a combined $759M.

Buyers outnumbered sellers: 126 funds opened new NBIX positions and 0 closed out — a net gain of 126 holders — while 0 added to existing stakes and 0 trimmed.

  • 126 institutional investors held Neurocrine Biosciences (NBIX) as of Q2 2013, up from 0 in Q1 2013.
  • Funds reported $759M of Neurocrine Biosciences stock for Q2 2013.
  • 126 funds opened new Neurocrine Biosciences positions in Q2 2013 and 0 closed out, a net change of +126 holders.

Based on aggregated 13F filings for Q2 2013.